References
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727–38.
Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129:3165–74.
Alexander TB, Lacayo NJ, Choi JK, Ribeiro RC, Pui CH, Rubnitz JE. Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia. J Clin Oncol. 2016;34:4094–101.
Fiedler W, Heuser M, Chromik J, Thol F, Bokemeyer C, Theile S, et al. Phase II results of Ara-C and idarubicin in combination with the selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML. Blood. 2016;128:341.
de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, et al. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2014;20:4–13.
Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133:1457–64.
Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003.
Huisman C, de Weger RA, de Vries L, Tilanus MG, Verdonck LF. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transpl. 2007;39:285–91.
Tyler PM, Servos MM, de Vries RC, Klebanov B, Kashyap T, Sacham S, et al. Clinical dosing regimen of selinexor maintains normal immune homeostasis and T-cell effector function in mice: implications for combination with immunotherapy. Mol Cancer Ther. 2017;16:428–39.
Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 2005;19:1416–23.
Rautenberg C, Pechtel S, Hildebrandt B, Betz B, Dienst A, Nachtkamp K, et al. Wilms’ tumor 1 gene expression using a Standardized European LeukemiaNet-Certified Assay compared to other methods for detection of minimal residual disease in myelodysplastic syndrome and acute myelogenous leukemia after allogeneic blood stem cell transplantation. Biol Blood Marrow Transplant. 2018;24:2337–43.
Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27:5195–201.
Acknowledgements
HL was supported by UCCCC pilot grant, Cancer Research Foundation Young investigator award and K12 Paul Calabresi award. The work is also supported by the University of Chicago Cancer Center Support Grant (CA014599).
Author information
Authors and Affiliations
Contributions
HL designed the trial. ASA, WS, RAL, SK, MB, and HL conducted the clinical trial. JHC, ASA, WS, RAL, SK, MB, and HL collected and analyzed the clinical data. NF processed patient samples and performed WT1 qRT-PCR. JHC conducted the statistical analysis of the clinical results. All authors contributed to the data analysis and wrote the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The trial was sponsored by Karyopharm. HL is the PI of the trial and has research support from Karyopharm and BMS. While several coauthors had research support from other pharmaceutical companies or served as consultant or advisory board members for other pharmaceutical companies, no one has conflict of interest associated with this current study.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Presented at: ASH 2017.
Rights and permissions
About this article
Cite this article
Cooperrider, J.H., Fulton, N., Artz, A.S. et al. Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 55, 2204–2206 (2020). https://doi.org/10.1038/s41409-020-0925-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-0925-2
- Springer Nature Limited